Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of ADL-018 vs Xolair in Healthy Adults
NCT05413161Phase 1Completed
- Sponsor
- Kashiv BioSciences
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adl018 in asthma, chronic spontaneous urticaria (CSU), nasal polyps and 1 more (3 arms), sponsored by Kashiv BioSciences. Primary endpoints: Maximum Observed Serum Concentration, Area Under the Serum Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 2 more. Started Jul 2022; status: completed.
02
Drugs
adl018
03
Conditions
asthmachronic spontaneous urticaria (CSU)nasal polypsfood allergy
Beyond the preview
Go deeper on NCT05413161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413161.